AML

>

Latest News

FDA Clears Phase 1 Study of Lomonitinib for R/R AML Treatment in the US
FDA Clears Phase 1 Study of Lomonitinib for R/R AML Treatment in the US

June 10th 2024

An investigational new drug application for lomonitinib has been cleared by the FDA for FLT3-mutated relapsed/refractory AML treatment, and a phase 1 trial evaluating the agent will begin in the US.

Phase 3 Study of Uproleselan Plus Chemo Fails to Improve Survival in R/R AML
Phase 3 Study of Uproleselan Plus Chemo Fails to Improve Survival in R/R AML

May 8th 2024

FDA Grants Orphan Drug Designation to IGNK001 in Acute Myeloid Leukemia
FDA Grants Orphan Drug Designation to IGNK001 in Acute Myeloid Leukemia

May 2nd 2024

Cell Therapies Emerge for the Treatment of Acute Myeloid Leukemia
Cell Therapies Emerge for the Treatment of Acute Myeloid Leukemia

April 26th 2024

FDA Grants Ziftomenib Breakthrough Therapy Designation in NPM1-Mutant AML
FDA Grants Ziftomenib Breakthrough Therapy Designation in NPM1-Mutant AML

April 22nd 2024

Video Series
Video Interviews

More News